Halozyme Therapeutics Inc (HALO : NASDAQ)
Common Stock
$121.51
USD
+4.69 (4.01%)
Last updated: 2026-10-15
Follow HALO
HALO
Halozyme Therapeutics Inc
WealthAwesomePerformance
1 Day
+4.01%
1 Week
+10.62%
1 Month
+14.36%
YTD
+77.21%
Key Statistics
Market Cap
$13.79B
52W High
$122.33
52W Low
$61.23
P/E Ratio
35.53
50 Day MA
$108.19
200 Day MA
$80.34
Beta
0.88
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/15/2026 | $118.35 | $122.33 | $117.38 | $121.51 | $121.51 | 2,470,000 |
| 10/14/2026 | $109.90 | $119.21 | $109.42 | $116.82 | $116.82 | 3,769,000 |
| 10/13/2026 | $111.92 | $111.92 | $108.80 | $109.62 | $109.62 | 1,772,622 |
| 10/12/2026 | $110.19 | $112.43 | $109.96 | $111.08 | $111.08 | 1,660,300 |
| 10/9/2026 | $109.70 | $112.65 | $109.70 | $110.42 | $110.42 | 1,845,300 |
| 10/8/2026 | $109.41 | $110.64 | $107.41 | $109.84 | $109.84 | 2,439,637 |
| 10/7/2026 | $111.62 | $114.00 | $110.16 | $110.79 | $110.79 | 2,179,273 |
| 10/6/2026 | $108.87 | $111.25 | $107.43 | $109.72 | $109.72 | 1,774,300 |
| 10/5/2026 | $109.62 | $109.87 | $107.68 | $108.31 | $108.31 | 1,449,718 |
| 10/2/2026 | $106.96 | $109.99 | $106.65 | $109.86 | $109.86 | 2,599,800 |
Analyst Price Targets
Based on 9 analysts covering HALO · as of Oct 16, 2026
Wall Street analysts forecast HALO stock price to fall 10.5% over the next 12 months.
Consensus
Buy4.33 / 5.00
Avg. Target
US$108.78
-10.5% Upside
Previously US$104.89 on Oct 14, 2026
Current Price
US$121.51
Last close
Analyst Breakdown (9 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HALO's historical volatility
30-Day Vol
32.9%
Annualized
90-Day Vol
42.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$145.27
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$128.96 | US$115.11 – US$144.49 |
| 60 trading days | US$136.87 | US$116.55 – US$160.74 |
| 90 trading days | US$145.27 | US$119.31 – US$176.87 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Financials
- Revenue (TTM)
- $1.66B
- EBITDA
- $1.05B
- Profit Margin
- 24.86%
- ROE (TTM)
- 173.67%
- EPS (Diluted)
- 3.42
- Book Value
- 1.26
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About HALO.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| KNDI | Kandi Technologies Group Inc | $4.11 | +928.50% |
| ESLA | Estrella Immunopharma Inc. | $0.54 | +68.35% |
| SDST | Stardust Power Inc. | $0.04 | +55.38% |
| XLAB | Exascale Labs Holdings Inc. Class A Common Stock | $1.36 | +49.70% |
| WETO | Webus International Limited Ordinary Shares | $1.22 | +46.88% |
| RITRF | Reitar Logtech Holdings Limited | $0.02 | +40.85% |
| DRMA | Dermata Therapeutics Inc | $0.91 | +37.19% |
| LESLQ | Leslie's, Inc. | $0.03 | +35.75% |
HALO.US news timeline
1 article covering HALO.US, most recent first
Latest